-DOCSTART- -X- O
The -X- _ O
respiratory -X- _ O
system -X- _ O
consists -X- _ O
of -X- _ O
an -X- _ O
integrated -X- _ O
network -X- _ O
of -X- _ O
organs -X- _ O
and -X- _ O
structures -X- _ O
that -X- _ O
primarilyfunction -X- _ O
for -X- _ O
gas -X- _ O
exchange. -X- _ O
In -X- _ O
mammals -X- _ O
, -X- _ O
oxygen -X- _ O
and -X- _ O
carbon -X- _ O
dioxide -X- _ O
are -X- _ O
transmitted -X- _ O
through -X- _ O
acomplex -X- _ O
respiratory -X- _ O
tract -X- _ O
, -X- _ O
consisting -X- _ O
of -X- _ O
the -X- _ O
nasal -X- _ O
passages -X- _ O
, -X- _ O
pharynx -X- _ O
, -X- _ O
larynx -X- _ O
, -X- _ O
and -X- _ O
lung. -X- _ O
Exposureto -X- _ O
ambient -X- _ O
air -X- _ O
throughout -X- _ O
the -X- _ O
lifespan -X- _ O
imposes -X- _ O
vulnerability -X- _ O
of -X- _ O
the -X- _ O
respiratory -X- _ O
system -X- _ O
toenvironmental -X- _ O
challenges -X- _ O
that -X- _ O
can -X- _ O
contribute -X- _ O
toward -X- _ O
development -X- _ O
of -X- _ O
disease. -X- _ O
The -X- _ O
importance -X- _ O
ofthe -X- _ O
respiratory -X- _ O
system -X- _ O
to -X- _ O
human -X- _ O
health -X- _ O
is -X- _ O
supported -X- _ O
by -X- _ O
statistics -X- _ O
from -X- _ O
the -X- _ O
Centers -X- _ O
for -X- _ O
DiseaseControl -X- _ O
and -X- _ O
Prevention -X- _ O
; -X- _ O
in -X- _ O
2015 -X- _ O
, -X- _ O
chronic -X- _ O
lower -X- _ O
respiratory -X- _ O
diseases -X- _ O
were -X- _ O
the -X- _ O
third -X- _ O
leading -X- _ O
causeof -X- _ O
death -X- _ O
in -X- _ O
the -X- _ O
United -X- _ O
States. -X- _ O
In -X- _ O
light -X- _ O
of -X- _ O
the -X- _ O
significant -X- _ O
mortality -X- _ O
associated -X- _ O
with -X- _ O
respiratoryconditions -X- _ O
that -X- _ O
afflict -X- _ O
all -X- _ O
ages -X- _ O
of -X- _ O
the -X- _ O
human -X- _ O
population -X- _ O
, -X- _ O
this -X- _ O
review -X- _ O
will -X- _ O
focus -X- _ O
on -X- _ O
basic -X- _ O
andpreclinical -X- _ O
research -X- _ O
conducted -X- _ O
in -X- _ O
nonhuman -X- _ B-Patient
primate -X- _ I-Patient
models -X- _ I-Patient
of -X- _ I-Patient
respiratory -X- _ I-Patient
disease. -X- _ I-Patient
In -X- _ O
comparisonwith -X- _ O
other -X- _ O
laboratory -X- _ O
animals -X- _ O
, -X- _ O
the -X- _ O
nonhuman -X- _ B-Outcome
primate -X- _ I-Outcome
lung -X- _ I-Outcome
most -X- _ I-Outcome
closely -X- _ I-Outcome
resembles -X- _ I-Outcome
the -X- _ I-Outcome
human -X- _ I-Outcome
lungin -X- _ I-Outcome
structure -X- _ I-Outcome
, -X- _ I-Outcome
physiology -X- _ I-Outcome
, -X- _ I-Outcome
and -X- _ I-Outcome
mucosal -X- _ I-Outcome
immune -X- _ I-Outcome
mechanisms. -X- _ I-Outcome
Studies -X- _ O
defining -X- _ O
the -X- _ O
influence -X- _ B-Outcome
ofinhaled -X- _ I-Outcome
microbes -X- _ I-Outcome
, -X- _ I-Outcome
pollutants -X- _ I-Outcome
, -X- _ I-Outcome
or -X- _ I-Outcome
allergens -X- _ I-Outcome
on -X- _ I-Outcome
the -X- _ I-Outcome
nonhuman -X- _ I-Outcome
primate -X- _ I-Outcome
lung -X- _ I-Outcome
have -X- _ I-Outcome
provided -X- _ I-Outcome
insight -X- _ I-Outcome
ondisease -X- _ I-Outcome
pathogenesis -X- _ I-Outcome
, -X- _ I-Outcome
with -X- _ I-Outcome
the -X- _ I-Outcome
potential -X- _ I-Outcome
for -X- _ I-Outcome
elucidation -X- _ I-Outcome
of -X- _ I-Outcome
molecular -X- _ I-Outcome
targets -X- _ I-Outcome
leading -X- _ I-Outcome
to -X- _ I-Outcome
newtreatment -X- _ I-Outcome
modalities. -X- _ I-Outcome
Vaccine -X- _ I-Outcome
trials -X- _ I-Outcome
in -X- _ I-Outcome
nonhuman -X- _ I-Outcome
primates -X- _ I-Outcome
have -X- _ I-Outcome
been -X- _ I-Outcome
crucial -X- _ I-Outcome
for -X- _ I-Outcome
confirmation -X- _ I-Outcome
ofsafety -X- _ I-Outcome
and -X- _ I-Outcome
protective -X- _ I-Outcome
efficacy -X- _ I-Outcome
against -X- _ I-Outcome
infectious -X- _ I-Outcome
diseases -X- _ I-Outcome
of -X- _ I-Outcome
the -X- _ I-Outcome
lung -X- _ I-Outcome
in -X- _ O
a -X- _ O
laboratory -X- _ O
animal -X- _ O
modelthat -X- _ O
recapitulates -X- _ O
pathology -X- _ O
observed -X- _ O
in -X- _ O
humans. -X- _ O
In -X- _ O
looking -X- _ O
to -X- _ O
the -X- _ O
future -X- _ O
, -X- _ O
nonhuman -X- _ O
primatemodels -X- _ O
of -X- _ O
respiratory -X- _ O
diseases -X- _ O
will -X- _ O
continue -X- _ O
to -X- _ O
be -X- _ O
instrumental -X- _ O
for -X- _ O
translating -X- _ O
biomedical -X- _ O
researchfor -X- _ O
improvement -X- _ O
of -X- _ O
human -X- _ O
health -X- _ O
. -X- _ O

